- Home
- ACIU vs CABA Comparison
ACIU vs CABA Comparison
Compare ACIU & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- CABA
- Stock Information
- Founded
- ACIU 2003
- CABA 2017
- Country
- ACIU Switzerland
- CABA United States
- Employees
- ACIU N/A
- CABA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- CABA Health Care
- Exchange
- ACIU Nasdaq
- CABA Nasdaq
- Market Cap
- ACIU 189.1M
- CABA 157.4M
- IPO Year
- ACIU 2016
- CABA 2019
- Fundamental
- Price
- ACIU $2.07
- CABA $1.70
- Analyst Decision
- ACIU Strong Buy
- CABA Strong Buy
- Analyst Count
- ACIU 1
- CABA 7
- Target Price
- ACIU $12.00
- CABA $14.43
- AVG Volume (30 Days)
- ACIU 125.1K
- CABA 1.8M
- Earning Date
- ACIU 08-05-2025
- CABA 08-07-2025
- Dividend Yield
- ACIU N/A
- CABA N/A
- EPS Growth
- ACIU N/A
- CABA N/A
- EPS
- ACIU N/A
- CABA N/A
- Revenue
- ACIU $32,014,254.00
- CABA N/A
- Revenue This Year
- ACIU N/A
- CABA N/A
- Revenue Next Year
- ACIU $533.21
- CABA N/A
- P/E Ratio
- ACIU N/A
- CABA N/A
- Revenue Growth
- ACIU 91.20
- CABA N/A
- 52 Week Low
- ACIU $1.43
- CABA $0.99
- 52 Week High
- ACIU $4.26
- CABA $7.69
- Technical
- Relative Strength Index (RSI)
- ACIU 55.57
- CABA 49.83
- Support Level
- ACIU $2.00
- CABA $1.60
- Resistance Level
- ACIU $2.15
- CABA $1.73
- Average True Range (ATR)
- ACIU 0.13
- CABA 0.11
- MACD
- ACIU -0.01
- CABA 0.01
- Stochastic Oscillator
- ACIU 80.92
- CABA 78.57
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.